Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs

Dow Jones

Apr 25, 2025

By Kelly Cloonan

Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.

The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.

The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.

Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.

The changes will extend Caribou's cash runway by one year, funding the current operating plan into the second half of 2027, it said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 24, 2025 17:08 ET (21:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2530539999"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530539999\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530539999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530539999","market":"fut","top_or_hot":-1,"title":"Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences Cuts Workforce, Shifts Pipeline to Focus on Key Oncology Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-25 05:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n</p>\n<p>\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n</p>\n<p>\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n</p>\n<p>\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n</p>\n<p>\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2025 17:08 ET (21:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2530539999","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530539999","pubTimestamp":1745528880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Caribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs.The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing.The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia.Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million.The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","CRBU":"Caribou Biosciences"},"translate_title":"Caribou Biosciences裁员，将产品线转移到关键肿瘤学项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\nCaribou Biosciences plans to trim its workforce and shift its pipeline as it looks to focus on its lead oncology programs. \n\n\n  The Berkeley, Calif.-biopharmaceutical company on Thursday said it plans to reduce its workforce by about 32%. Such cuts would amount to roughly 47 employees, based on the total workforce of 147 full-time employees according to its latest annual filing. \n\n\n  The company is also discontinuing preclinical research as well as Phase 1 trials of treatments for lupus and relapsed or refractory acute myeloid leukemia. \n\n\n  Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. \n\n\n  The changes will extend Caribou's cash runway by one year, funding the  current operating plan into the second half of 2027, it said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2025 17:08 ET (21:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}